A steady increase in serum ALT/AST activity accompanied the progression of liver fibrosis in the mice (0‐8 weeks of treatment, P < 0.001 at 8 weeks vs the 0 weeks group), indicating deterioration of liver health (Figure 6A). The gene discussed is GPT; the disease is Hepatic fibrosis.